MiR-1224-5p acts as a tumor suppressor by targeting CREB1 in malignant gliomas

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Dysregulation of microRNA-1224-5p (miR-1224-5p) is implicated in various human cancers.
• The role of miR-1224-5p in glioma, a primary brain tumor, remains largely uncharacterized.
• Understanding miR-1224-5p's function is crucial for developing novel glioma therapies.

Purpose of the Study:

• To investigate the expression and functional significance of miR-1224-5p in glioma.
• To identify the molecular targets and signaling pathways regulated by miR-1224-5p in glioma cells.
• To explore the potential of miR-1224-5p as a therapeutic agent for malignant gliomas.

Main Methods:

• Analysis of miR-1224-5p expression in 198 glioma samples from the Chinese Glioma Genome Atlas dataset.
• In situ hybridization to validate differential miR-1224-5p expression.
• In vitro experiments assessing the effects of miR-1224-5p on glioma cell proliferation, invasion, and apoptosis.
• Luciferase reporter assays to confirm CREB1 as a direct target of miR-1224-5p.

Main Results:

• miR-1224-5p expression was significantly decreased in high-grade gliomas compared to low-grade gliomas.
• Lower miR-1224-5p expression correlated with poorer overall survival in glioblastoma patients.
• Overexpression of miR-1224-5p inhibited glioma cell proliferation and invasion while promoting apoptosis.
• miR-1224-5p directly targets cAMP response element-binding protein 1 (CREB1), downregulating its expression and downstream targets MMP-9 and BCL-2.
• CREB1 overexpression reversed the tumor-suppressive effects of miR-1224-5p.

Conclusions:

• miR-1224-5p functions as a tumor suppressor in malignant gliomas.
• The miR-1224-5p/CREB1 axis plays a critical role in regulating glioma cell behavior.
• miR-1224-5p represents a potential therapeutic target for glioma treatment.